Aztreonam inhalation - Gilead Sciences

Drug Profile

Aztreonam inhalation - Gilead Sciences

Alternative Names: AI - Gilead; AZLI; Aztreonam lysine; Cayston; Corus 1020; GS-9268

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Gilead Sciences
  • Class Antibacterials; Monobactams; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis-associated respiratory tract infections
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cystic fibrosis-associated respiratory tract infections
  • Discontinued Bronchiectasis; Burkholderia infections

Most Recent Events

  • 06 Apr 2015 Discontinued - Phase-III for Bronchiectasis in USA, Canada, Australia, United Kingdom, Belgium, Netherlands, France, Italy, Germany and Spain (Inhalation) before April 2015
  • 06 Apr 2015 Discontinued - Phase-III for Burkholderia infections in USA and Canada (Inhalation) before April 2015
  • 06 Apr 2015 Launched for Cystic fibrosis-associated respiratory tract infections in Germany, Latvia, Lithuania, Spain and Switzerland (Inhalation) before April 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top